EN DE

DAIHAN Scientific Co (131220) Fair Value & Analysis

Technology · KR · Market cap 28.6B KRW

DS DAIHAN Scientific Co 131220 · KQ
Price3,340 KRW
Fair Value8,806 KRW
Upside+163.7%
Quality61/100
Watch DAIHAN Scientific Co for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 4.0% net margin
Low debt · generates free cash flow
3.21% dividend yield
Ranks above peers (8/10)
Narrow moat 37/100
Evidence: Medium Range 6,605 KRW – 11,008 KRW Share as image

Fair value as of: Jul 22, 2026

From 26 valuation models · updated 19 days ago

Share price −12.3% over the past month.

A solid business, screening 164% undervalued on our models.

What matters now

  • The price is below even our cautious bear case (6,605 KRW). The market is more pessimistic than our downside scenario.
  • Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

18,878 KRW 3,250 KRW Fair Value 8,806 KRW Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.

How to read this chart

60‑month range 3,250 KRW – 18,878 KRW · fair‑value band 6,605 KRW – 11,008 KRW · the 3,340 KRW price screens below the 8,806 KRW fair value. Dashed = 300-day average. As of Jul 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

DAIHAN Scientific Co (131220) currently trades at 3,340 KRW, while our model-based Fair Value estimate is 8,806 KRW, implying the stock looks roughly 163.7% undervalued today. The Quality Score stands at 61/100 (solid quality), in the Technology sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, DAIHAN Scientific Co generated revenue of 83.0B KRW at a net margin of 4.0%. Revenue grew 12.1% year over year. It earns a return on equity of 8.9%. Fundamentals as of Jul 22, 2026

Our scenario range runs from 6,605 KRW (bear case) to 11,008 KRW (bull case); at 3,340 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 35% below its 52-week high, currently below its 200-day average. For context, the median of 10 Technology peers we cover trades at -45% fair-value upside, at 164%, 131220 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 8,765 KRW 12,935 KRW 19,016 KRW 80
Residual Income 4,922 KRW 5,201 KRW 5,665 KRW 76
Rev-Margin DCF 7,671 KRW 11,880 KRW 16,834 KRW 74
All 26 models by family
DCF Models
FCF DCF 8,662 KRW 13,447 KRW 20,926 KRW 38
Owner Earnings 8,068 KRW 12,499 KRW 19,422 KRW 31
5Y Revenue Exit 7,671 KRW 11,876 KRW 17,270 KRW 39
5Y EBITDA Exit 9,041 KRW 14,485 KRW 20,900 KRW 41
5Y P/E Exit 7,299 KRW 11,169 KRW 15,257 KRW 38
10Y Revenue Exit 7,740 KRW 11,699 KRW 17,095 KRW 36
10Y EBITDA Exit 8,830 KRW 13,529 KRW 19,911 KRW 37
10Y P/E Exit 7,712 KRW 11,204 KRW 15,533 KRW 35
Earnings-Based
Graham-Dodd 2,994 KRW 10,126 KRW 13,574 KRW 54
Lynch FV 2,315 KRW 3,307 KRW 4,299 KRW 50
PEG = 1.0 2,315 KRW 3,307 KRW 4,299 KRW 46
EPV 6,116 KRW 7,023 KRW 7,817 KRW 59
Dividend Discount
Gordon GGM 850.46 KRW 1,768 KRW 2,805 KRW 70
DDM Multi-Stage 850.46 KRW 1,462 KRW 1,856 KRW 61
Multiples
P/E Multiple 6,605 KRW 8,806 KRW 11,008 KRW 63
P/S Multiple 5,614 KRW 7,485 KRW 9,356 KRW 58
P/B Multiple 5,614 KRW 7,485 KRW 9,356 KRW 55
EV/EBIT 10,692 KRW 14,032 KRW 17,371 KRW 53
EV/EBITDA 10,240 KRW 13,429 KRW 16,618 KRW 54
EV/Revenue 7,427 KRW 10,321 KRW 13,215 KRW 43
Asset-Based
NCAV (Graham) 3,017 KRW 4,043 KRW 6,035 KRW 50
Growth DCF
Growth DCF 8,765 KRW 12,935 KRW 19,016 KRW 80
Rev-Margin DCF 7,671 KRW 11,880 KRW 16,834 KRW 74
Economic Profit
Residual Income 4,922 KRW 5,201 KRW 5,665 KRW 76
ROIC Compounder 6,142 KRW 7,650 KRW 9,643 KRW 72
Growth Earnings
Growth-Adj P/E 5,658 KRW 8,082 KRW 10,507 KRW 68

Widest divergence: Growth DCF (11,880 KRW) versus Dividend Discount (1,462 KRW). Highest evidence: Growth DCF (80).

Notify me when 131220 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 83.0B KRW
Revenue growth (YoY) +12.1%
Net margin 4.0%
Return on equity 8.9%
Free cash flow 5.1B KRW FY2025
Operating margin 5.5%
More key figures
Dividend yield 3.3%
EPS growth (YoY) +5.3%

Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 61/100

Of which business quality 63 · Market factors (momentum, volatility) 28

Profitability 49
Margins and returns on capital today
Quality Growth 62
Are margins and returns improving?
Cashflow 62
Earnings quality: real cash, not paper profit
Fin. Strength 84
Balance sheet, leverage, solvency risk
Investment 77
Disciplined investing over empire-building
Low Volatility 82
Calm price path (market factor)
Momentum 6
Price trend over the last 3–12 months (market factor)
52W Momentum 3
Distance to the 52-week high (market factor)
Net Issuance 42
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

DAIHAN Scientific Co., Ltd. manufactures and supplies laboratory instruments and medical devices in South Korea and internationally.

Full company description

DAIHAN Scientific Co., Ltd. manufactures and supplies laboratory instruments and medical devices in South Korea and internationally. It offers autoclaves, balances, centrifuges, evaporators, gel documentation systems, heating stirrers, mills, shakers, viscometers, refrigerators/freezers, bath circulators, chillers/cooling circulators, freeze dry systems, glass/labware washers, heating mantles, hotplates, ovens, stirrers, water purification products, incubators, baths, desiccator cabinets, furnaces, heating blocks/dry bath incubators, homogenizers, magnifiers, reactors, and ultrasonic cleaners, as well as smart-lab and touch screen systems under the Wisd brand. It also provides DAIHAN Smart-Lab controller for data recording, storage management, and self-diagnostic functions; and Wire App and web services that enables gathering, analyzing, and sharing of experimental data. The company was founded in 1980 and is headquartered in Wonju-si, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

DAIHAN Scientific Co reported revenue of 81.1B KRW in FY2025 versus 66.3B KRW in FY2021, a compound +5.2%/yr. Reported net income was 3.3B KRW in FY2025, compounding −3.4%/yr from FY2021.

Growth Quality 65/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
81.1B KRW
Latest YoY
+13.1%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+3.9%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+5.7%
Avg. growth/yr (13Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+5.8%
Revenue +5.2%/yr
FY21 66.3B KRW
FY22 72.3B KRW
FY23 73.7B KRW
FY24 71.7B KRW
FY25 81.1B KRW
Net income −3.4%/yr
FY21 3.8B KRW
FY22 4.7B KRW
FY23 3.8B KRW
FY24 2.7B KRW
FY25 3.3B KRW

Watch 131220: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "DAIHAN Scientific Co Fair Value". https://www.fairvalue-calculator.com/stock/131220

Peer Group

Scientific & Technical Instruments · 161 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 61 · Above median
Fair Value upside +164% · Top 25%
Return on equity (TTM) 9% · Above median
Return on assets 5% · Above median
Net margin (TTM) 4% · Below median
Operating margin (TTM) 6% · Below median
Revenue growth 12% · Above median
Dividend yield (TTM) 3.2% · Top 25%

Valuation Multiples vs Scientific & Technical Instruments median · lower = cheaper

P/FCF 0.0× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 0
FUTURE 61 · sector 34
PAST 36 · sector 25
HEALTH 100 · sector 98
DIVIDEND 64 · sector 24

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Scientific & Technical Instruments stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).

Stock Price Fair Value vs Fair Value
Keysight Technologies, Inc KEYS $315.90 $84.16 -73%
Garmin Ltd GRMN $241.76 $146.67 -39%
Teledyne Technologies Incorporated TDY $635.52 $367.58 -42%
Chroma ATE Inc 2360 1,905 TWD 286.15 TWD -85%
Hexagon AB HEXAB kr 80.10 kr 52.93 -34%
MKS Inc MKSI $324.69 $77.46 -76%
AVIC Chengdu Aircraft Company 302132 ¥52.91 ¥34.47 -35%
Fortive Corporation FTV $61.78 $33.84 -45%
Trimble Inc TRMB $52.72 $24.47 -54%
Cognex Corporation CGNX $64.07 $13.75 -79%

Compare DAIHAN Scientific Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is DAIHAN Scientific Co (131220) overvalued or undervalued?
As of Jul 22, 2026, our model estimates a fair value of 8,806 KRW versus a price of 3,340 KRW, about +164% (undervalued).
What is the fair value of 131220?
Our model-based fair value for DAIHAN Scientific Co is 8,806 KRW (as of Jul 22, 2026), built from audited fundamentals. The current price is 3,340 KRW.
What is the quality score of 131220?
DAIHAN Scientific Co has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of DAIHAN Scientific Co (131220)?
DAIHAN Scientific Co reported trailing-twelve-month revenue of about 83.0B KRW (latest available figure, as of Jul 22, 2026).
What is the net profit margin of 131220?
The net profit margin of DAIHAN Scientific Co is about 4.0%, meaning it keeps roughly 4.0% of revenue as net income. Based on the latest reported figures.
Does DAIHAN Scientific Co pay a dividend?
DAIHAN Scientific Co currently shows a dividend yield of about 3.29% relative to its recent price (as of Jul 22, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track DAIHAN Scientific Co and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.